Luis D Medina1, Stephanie Torres1, Enrique Alvarez2, Brooke Valdez2, Kavita V Nair2,3. 1. Department of Psychology, University of Houston, USA. 2. Department of Neurology, University of Colorado School of Medicine, USA. 3. University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA.
Abstract
BACKGROUND: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time-consuming and examination of their validity for use in an MS sample has been limited. OBJECTIVE: To determine the discriminant validity of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms in a real-world MS clinic population. DESIGN/ METHODS: Neuro-QoL is a series of questionnaires for tracking physical function, emotional/cognitive health, and social abilities in clinical populations. Neuro-QoL data from 902 MS patients were analyzed for psychometric properties and factor structure. RESULTS: Neuro-QoL demonstrated acceptable reliability in the moderate-to-good ranges. Moderate support for convergent validity was observed with other measures of MS quality of life, disease severity, and symptoms. However, results from a confirmatory factor analysis suggested poor model fit for most of the 12 domains tested. CONCLUSIONS: These findings support the utility of some of the Neuro-QoL questionnaires in evaluating MS-related PROs. However, additional research may help abridge and strengthen these measures for use in this population.
BACKGROUND: Patient-reported outcome (PRO) measures have been shown to be effective for tracking treatment outcomes in multiple sclerosis (MS). However, collecting PROs as part of the clinical standard of care can be time-consuming and examination of their validity for use in an MS sample has been limited. OBJECTIVE: To determine the discriminant validity of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms in a real-world MS clinic population. DESIGN/ METHODS: Neuro-QoL is a series of questionnaires for tracking physical function, emotional/cognitive health, and social abilities in clinical populations. Neuro-QoL data from 902 MS patients were analyzed for psychometric properties and factor structure. RESULTS: Neuro-QoL demonstrated acceptable reliability in the moderate-to-good ranges. Moderate support for convergent validity was observed with other measures of MS quality of life, disease severity, and symptoms. However, results from a confirmatory factor analysis suggested poor model fit for most of the 12 domains tested. CONCLUSIONS: These findings support the utility of some of the Neuro-QoL questionnaires in evaluating MS-related PROs. However, additional research may help abridge and strengthen these measures for use in this population.
Authors: Karon F Cook; Michael A Kallen; Charles Bombardier; Alyssa M Bamer; Seung W Choi; Jiseon Kim; Rana Salem; Dagmar Amtmann Journal: Qual Life Res Date: 2016-07-14 Impact factor: 4.147
Authors: David Victorson; Jose E Cavazos; Gregory L Holmes; Anthony T Reder; Valerie Wojna; Cindy Nowinski; Deborah Miller; Sarah Buono; Allison Mueller; Claudia Moy; David Cella Journal: Epilepsy Behav Date: 2013-12-20 Impact factor: 2.937
Authors: Deborah M Miller; Francois Bethoux; David Victorson; Cindy J Nowinski; Sarah Buono; Jin-Shei Lai; Katy Wortman; James L Burns; Claudia Moy; David Cella Journal: Mult Scler Date: 2015-08-03 Impact factor: 6.312
Authors: Tasneem L Talib; Paige DeChant; Jacob Kean; Patrick O Monahan; David A Haggstrom; Madison E Stout; Kurt Kroenke Journal: Qual Life Res Date: 2018-08-14 Impact factor: 4.147
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422